Clinical Trial Update: Cetuximab Plus Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Cancer of the Pancreas [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating cetuximab plus gemcitabine for pancreatic cancer (locally advanced, metastatic, or recurrent) has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• ERBITUX (cetuximab)
• Gemzar (gemcitabine)

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Pancreatic Cancer | Phase 2 | Status: WITHDRAWN